Childhood CCL18, CXCL10 and CXCL11 levels differentially relate to and predict allergy development.
CCL18
CXCL10
CXCL11
allergy
asthma
chemokine
sensitization
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
28
05
2021
received:
19
04
2021
accepted:
02
06
2021
pubmed:
9
6
2021
medline:
8
1
2022
entrez:
8
6
2021
Statut:
ppublish
Résumé
Chemokines are important mediators in immune cell recruitment, contributing to allergy development. However, extensive studies of chemokines in the circulation in relation to the presence and development of allergic diseases remain scarce. Our aim was to investigate associations of circulating allergy-related chemokines with the development of asthma and sensitization cross-sectionally and longitudinally in a population-based cohort. The chemokines CCL17, CCL22, CXCL10, CXCL11 and CCL18 were measured in plasma samples from children in the Manchester Asthma and Allergy Study. Samples were available from cord blood at birth (n = 376), age 1 (n = 195) and age 8 (n = 334). Cross-sectional and longitudinal association analyses were performed in relation to asthma and allergic sensitization, as well as allergic phenotype clusters previously derived using machine learning in the same study population. In children with asthma and/or allergic sensitization, CCL18 levels were consistently elevated at 1 and/or 8 years of ages. In a longitudinal model including information on asthma from 4 time points (5, 8, 11 and 16 years of ages), we observed a significant association between increasing CCL18 levels at age 1 and a higher risk of asthma from early school age to adolescence (OR = 2.9, 95% CI 1.1-7.6, p = .028). We observed similar associations in longitudinal models for allergic sensitization. Asthma later in life was preceded by increased CXCL10 levels after birth and decreased CXCL11 levels at birth. Elevated CCL18 levels throughout childhood precede the development of asthma and allergic sensitization. The Th1-associated chemokines CXCL10 and CXCL11 also associated with the development of both outcomes, with differential temporal effects.
Sections du résumé
BACKGROUND
Chemokines are important mediators in immune cell recruitment, contributing to allergy development. However, extensive studies of chemokines in the circulation in relation to the presence and development of allergic diseases remain scarce. Our aim was to investigate associations of circulating allergy-related chemokines with the development of asthma and sensitization cross-sectionally and longitudinally in a population-based cohort.
METHODS
The chemokines CCL17, CCL22, CXCL10, CXCL11 and CCL18 were measured in plasma samples from children in the Manchester Asthma and Allergy Study. Samples were available from cord blood at birth (n = 376), age 1 (n = 195) and age 8 (n = 334). Cross-sectional and longitudinal association analyses were performed in relation to asthma and allergic sensitization, as well as allergic phenotype clusters previously derived using machine learning in the same study population.
RESULTS
In children with asthma and/or allergic sensitization, CCL18 levels were consistently elevated at 1 and/or 8 years of ages. In a longitudinal model including information on asthma from 4 time points (5, 8, 11 and 16 years of ages), we observed a significant association between increasing CCL18 levels at age 1 and a higher risk of asthma from early school age to adolescence (OR = 2.9, 95% CI 1.1-7.6, p = .028). We observed similar associations in longitudinal models for allergic sensitization. Asthma later in life was preceded by increased CXCL10 levels after birth and decreased CXCL11 levels at birth.
CONCLUSION
Elevated CCL18 levels throughout childhood precede the development of asthma and allergic sensitization. The Th1-associated chemokines CXCL10 and CXCL11 also associated with the development of both outcomes, with differential temporal effects.
Substances chimiques
CCL18 protein, human
0
CXCL10 protein, human
0
CXCL11 protein, human
0
Chemokine CXCL10
0
Chemokine CXCL11
0
Chemokines, CC
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1824-1832Subventions
Organisme : Medical Research Council
ID : MR/L012693/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K002449/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S025340/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Clin Respir J. 2015;2(1):24642.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429-440.
Oksel C, Haider S, Fontanella S, Frainay C, Custovic A. Classification of pediatric asthma: from phenotype discovery to clinical practice. Front Pediatr. 2018;6:258.
Howard R, Rattray M, Prosperi M, Custovic A. Distinguishing asthma phenotypes using machine learning approaches. Curr Allergy Asthma Rep. 2015;15(7):38.
Pease J, Williams T. Chemokines and their receptors in allergic disease. J Allergy Clin Immunol. 2006;118(2):305-318.
Sandberg M, Frykman A, Ernerudh J, et al. Cord blood cytokines and chemokines and development of allergic disease. Pediatr Allergy Immunol. 2009;20(6):519-527.
Abelius MS, Ernerudh J, Berg G, Matthiesen L, Nilsson LJ, Jenmalm MC. High cord blood levels of the T-helper 2-associated chemokines CCL17 and CCL22 precede allergy development during the first 6 years of life. Pediatr Res. 2011;70(5):495-500.
Abrahamsson TR, Sandberg Abelius M, Forsberg A, Björkstén B, Jenmalm MC. A Th1/Th2-associated chemokine imbalance during infancy in children developing eczema, wheeze and sensitization. Clin Exp Allergy. 2011;41(12):1729-1739.
Southworth T, Pattwell C, Khan N, et al. Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma. Cytokine. 2020;125:154857.
Ghebre MA, Pang PH, Desai D, et al. Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum. BMC Pulm Med. 2019;19(1):144.
Reubsaet LL, Meerding J, de Jager W, et al. Plasma chemokines in early wheezers predict the development of allergic asthma. Am J Respir Crit Care Med. 2013;188(8):1039-1040.
Chenivesse C, Tsicopoulos A. CCL18 - beyond chemotaxis. Cytokine. 2018;109:52-56. https://doi.org/10.1016/j.cyto.2018.01.023
Custovic A, Simpson BM, Murray CS, Lowe L, Woodcock A. The national asthma campaign manchester asthma and allergy study. Pediatr Allergy Immunol. 2002;13(s15):32-37.
Simpson A, Tan VYF, Winn J, et al. Beyond atopy. Am J Respir Crit Care Med. 2010;181(11):1200-1206.
Fontanella S, Frainay C, Murray CS, Simpson A, Custovic A. Machine learning to identify pairwise interactions between specific IgE antibodies and their association with asthma: a cross-sectional analysis within a population-based birth cohort. PLoS Medicine. 2018;15(11):e1002691.
Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Medicine. 2014;11(10):e1001748.
Deliu M, Fontanella S, Haider S, et al. Longitudinal trajectories of severe wheeze exacerbations from infancy to school age and their association with early-life risk factors and late asthma outcomes. Clin Exp Allergy. 2020;50(3):315-324.
Hon K, Ching GK, Ng P, Leung T. Exploring CCL18, eczema severity and atopy: PARC and eczema. Pediatr Allergy Immunol. 2011;22(7):704-707.
Günther C, Bello-Fernandez C, Kopp T, et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol. 2005;174(3):1723-1728.
Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207-215.
Romagnani P, Annunziato F, Lazzeri E, et al. Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) αβ+CD8+ single-positive T cells, TCRγδ+ T cells, and natural killer-type cells in human thymus. Blood. 2001;97(3):601-607.
Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel Non-ELR CXC chemokine with potent activity on activated T Cells through selective high affinity binding to CXCR3. J Exp Med. 1998;187(12):2009-2021.
Wark PAB, Bucchieri F, Johnston SL, et al. IFN-γ-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations. J Allergy Clin Immunol. 2007;120(3):586-593.
Moskwa S, Piotrowski W, Marczak J, et al. Innate immune response to viral infections in primary bronchial epithelial cells is modified by the atopic status of asthmatic patients. Allergy Asthma Immunol Res. 2018;10(2):144.